Improve Human Health to Preserve Patients’ Dignity

Leading new drug development for genitourinary tumors & other related diseases

Highlights

Asieris Pharmaceuticals Unveils 2023 Annual Report, Core Product APL-1702 Succeeds in Global Phase III Clinical Trials, APL-1706 obtains NDA acceptance domestically, Specialty Commercial Team Generates Sustained Revenue Streams

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Treatment Areas

Bladder Cancer

Lack of oral therapy for non-muscle invasive bladder cancer (NMIBC) patients with improved patient compliance and less adverse effects from intravesical administration.

Precancerous Cervical Dysplasia

In urgent need of safe and effective options for patients with cervical precancerous lesions, currently treated by traditional surgical methods.

Global Partnership

News & Updates

Asieris Pharmaceuticals Unveils 2023 Annual Report, Core Product APL-1702 Succeeds in Global Phase III Clinical Trials, APL-1706 obtains NDA acceptance domestically, Specialty Commercial Team Generates Sustained Revenue Streams

Asieris Pharmaceuticals Releases the Drug and Equipment Performance Results from the Phase III Clinical Study of the Bladder Cancer Diagnostic and Management Drug APL-1706 in Combination with HD 4K Blue Light Cystoscopy

Asieris Pharmaceuticals to Present the Drug and Equipment Performance Results from the Phase III Clinical Study of the Bladder Cancer Diagnostic and Management Drug APL-1706 in Combination with HD 4K Blue Light Cystoscopy

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

Asieris’ Two Research Achievements to be Presented at the 2024 American Association for Cancer Research Annual Meeting, Exploring More Treatment Possibilities

Asieris to Unveil Results of the international multicenter Phase III clinical Study for APL-1702, a non-surgical treatment for cervical HSIL, at the 2024 SGO Annual meeting

Technology Platform